Jack Khattar; President, Chief Executive Officer, Secretary, Director; Supernus Pharmaceuticals Inc Timothy Dec; Chief Financial Officer, Senior Vice President; Supernus Pharmaceuticals Inc Good ...
Stifel Nicolaus analyst Annabel Samimy maintained a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price ...
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after the bell. Here’s what ...
Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full yea ...
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results , with sales up 6% year on ...
On a per-share basis, the Rockville, Maryland-based company said it had net income of 27 cents. Earnings, adjusted for amortization costs and stock option expense, were 75 cents per share.
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) will likely be releasing its earnings data after the market closes ...
After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...
Hosted on MSN6d
Cantor Fitzgerald Downgrades Supernus Pharmaceuticals (SUPN)Fintel reports that on February 19, 2025, Cantor Fitzgerald downgraded their outlook for Supernus Pharmaceuticals ...
7d
Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...
Supernus Pharmaceuticals (NASDAQ:SUPN) stock drops as depression candidate SPN-820 misses main goals in Phase 2b trial. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback